nach oben

Current Cardiology Reports

Erschienen in:

17.01.2022 | Ischemic Heart Disease (D Mukherjee, Section Editor)

Cardiovascular Morbidity in Individuals with Impaired FEV1

verfasst von: Joscilin Mathew, Nils Patrick Nickel

Erschienen in: Current Cardiology Reports | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review is intended to give an overview of the epidemiology of cardiovascular morbidity and mortality in patients with impaired lung function with an emphasis on patients with COPD.

Recent Findings

Despite shared risk factors, lung disease is an emerging independent risk factor for cardiovascular disease and cardio-vascular disease (CVD) outcomes. Both CVD and chronic lung disease contribute significantly to overall mortality. Especially patients with chronic obstructive pulmonary disease (COPD) are at high risk for CVD-related mortality.

Summary

In patients with chronic lung disease, a low index of suspicion should be maintained to assess for CVD and vice versa. Early detection of chronic lung disease as a potentially modifiable CVD risk factor could have important impact on patient outcomes.

Ford ES, Croft JB, Mannino DM, et al. COPD surveillance—United States, 1999–2011. Chest. 2013;144:284–305. https://doi.org/10.1378/chest.13-0809.

Mannino DM, McBurnie MA, Tan W, et al. Restricted spirometry in the burden of lung disease study. Int J Tuberc Lung Dis. 2012;16:1405–1411. https://doi.org/10.5588/ijtld.12.0054.

Pelkonen M, Tukiainen H, Tervahauta M, et al. Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men. Thorax. 2000;55:746–750. https://doi.org/10.1136/thorax.55.9.746.

Hole DJ, Watt GC, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313:711–715; discussion 715–716. https://doi.org/10.1136/bmj.313.7059.711.

Martinez FJ, Han MK, Allinson JP, et al. At the root: defining and halting progression of early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197:1540–1551. https://doi.org/10.1164/rccm.201710-2028PP.

Conrad N, Judge A, Canoy D, et al. Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86000 individuals. JAMA Cardiol. 2019;4:1102–1111. https://doi.org/10.1001/jamacardio.2019.3593.

Ma J, Ward EM, Siegel RL, et al. Temporal trends in mortality in the United States, 1969–2013. JAMA. 2015;314:1731–1739. https://doi.org/10.1001/jama.2015.12319.

Kalhan R, Arynchyn A, Colangelo LA, et al. Lung function in young adults predicts airflow obstruction 20 years later. Am J Med. 2010;123:468 e461–467. https://doi.org/10.1016/j.amjmed.2009.07.037.

Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010;80:112–119. https://doi.org/10.1159/000281880.

10.

Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65:956–962. https://doi.org/10.1136/thx.2009.128082.

11.

Sode BF, Dahl M and Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish Nationwide Study of 7.4 million individuals. Eur Heart J. 2011;32:2365–2375. https://doi.org/10.1093/eurheartj/ehr338.

12.

Behar S, Panosh A, Reicher-Reiss H, et al. Prevalence and prognosis of chronic obstructive pulmonary disease among 5,839 consecutive patients with acute myocardial infarction. SPRINT Study Group. Am J Med 1992;93:637–641. https://doi.org/10.1016/0002-9343(92)90196-i.

13.

Soriano JB, Rigo F, Guerrero D, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest. 2010;137:333–340. https://doi.org/10.1378/chest.09-1264.

14.

•• Duong M, Islam S, Rangarajan S, et al. Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. Lancet Glob Health. 2019;7:e613-e623. https://doi.org/10.1016/S2214-109X(19)30070-1. FEV1 is an independent predictor of CVD, even across the clinically normal range (mild to moderate impairment).

15.

Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada: cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70. https://doi.org/10.1016/J.ANNEPIDEM.2005.04.008.CrossRefPubMed

16.

Kannel WB, Hubert H, Lew EA. Vital capacity as a predictor of cardiovascular disease: The Framingham study. Am Heart J. 1983;105:311–5. https://doi.org/10.1016/0002-8703(83)90532-X.CrossRefPubMed

17.

Schroeder EB, Welch VL, Couper D, et al. Lung function and incident coronary heart disease: the atherosclerosis risk in communities study. Am J Epidemiol. 2003;158:1171–81. https://doi.org/10.1093/aje/kwg276.CrossRefPubMed

18.

Bikov A, Lange P, Anderson JA, et al. FEV1 is a stronger mortality predictor than FVC in patients with moderate copd and with an increased risk for cardiovascular disease. Int J COPD. 2020;15:1135–42. https://doi.org/10.2147/COPD.S242809.CrossRef

19.

Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med. 2008;178:1257–61. https://doi.org/10.1164/rccm.200805-725OC.CrossRefPubMed

20.

Liu H, Fu Y, Wang K. Asthma and risk of coronary heart disease: a meta-analysis of cohort studies. Ann Allergy Asthma Immunol. 2017;118:689–95. https://doi.org/10.1016/j.anai.2017.03.012.CrossRefPubMed

21.

Canepa M, Straburzynska-Migaj E, Drozdz J, et al. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2018;20:100–110. https://doi.org/10.1002/ejhf.964.

22.

Lopez-Sanchez M, Munoz-Esquerre M, Huertas D, et al. High prevalence of left ventricle diastolic dysfunction in severe COPD associated with a low exercise capacity: a cross-sectional study. PLoS One. 2013;8:e68034. https://doi.org/10.1371/journal.pone.0068034.

23.

Stone IS, Barnes NC, James WY, et al. Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease. a randomized controlled trial. Am J Respir Crit Care Med. 2016;193:717–726. https://doi.org/10.1164/rccm.201508-1647OC.

24.

• Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6:368–378. https://doi.org/10.1016/s2213-2600(18)30054-7. This study demonstrates that bronchodilators have a direct hemodynamic effect on left-ventricular function. Early use of bronchodialtors in patients with COPD could serve as a preventative measure to reduce CVD in patients with COPD.

25.

Engstrom G, Melander O, Hedblad B. Population-based study of lung function and incidence of heart failure hospitalisations. Thorax. 2010;65:633–638. https://doi.org/10.1136/thx.2010.135392.

26.

Cuttica MJ, Colangelo LA, Shah SJ, et al. Loss of lung health from young adulthood and cardiac phenotypes in middle age. Am J Respir Crit Care Med. 2015;192:76–85. https://doi.org/10.1164/rccm.201501-0116OC.

27.

Chronic Cor Pulmonale. Report of an expert committee. World Health Organ Tech Rep Ser. 1961;213:35.

28.

Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;5. https://doi.org/10.1183/13993003.01914-2018.

29.

Boerrigter BG, Bogaard HJ, Trip P, et al. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest. 2012;142:1166–1174. https://doi.org/10.1378/chest.11-2798.

30.

McCord J, Borzak S. Multifocal atrial tachycardia. Chest. 1998;113: 203–209. https://doi.org/10.1378/chest.113.1.203.

31.

Shih HT, Webb CR, Conway WA, et al. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest. 1988;94:44–48. https://doi.org/10.1378/chest.94.1.44.

32.

Buch P, Friberg J, Scharling H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003;21:1012–1016. https://doi.org/10.1183/09031936.03.00051502.

33.

Li J, Agarwal SK, Alonso A, et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2014;129:971–980. https://doi.org/10.1161/CIRCULATIONAHA.113.004050.

34.

Tükek T, Yildiz P, Atilgan D, et al. Effect of diurnal variability of heart rate on development of arrhythmia in patients with chronic obstructive pulmonary disease. Int J Cardiol. 2003;88:199–206. https://doi.org/10.1016/s0167-5273(02)00402-3.CrossRefPubMed

35.

Iribarren C, Round AD, Peng JA, et al. Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis. Ann Noninvasive Electrocardiol. 2014;19:490–500. https://doi.org/10.1111/anec.12157.

36.

Gaita F, Giustetto C, Bianchi F, et al. Short QT Syndrome: a familial cause of sudden death. Circulation. 2003;108:965–970. https://doi.org/10.1161/01.CIR.0000085071.28695.C4.

37.

Warnier MJ, Blom MT, Bardai A, et al. Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study. PLoS One. 2013;8:e65638. https://doi.org/10.1371/journal.pone.0065638.

38.

Lahousse L, Niemeijer MN, van den Berg ME, et al. Chronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam study. Eur Heart J. 2015;36:1754–1761. https://doi.org/10.1093/eurheartj/ehv121.

39.

Liao KM, Kuo LT, Lu HY. Increased risk of peripheral arterial occlusive diseases in patients with chronic obstructive pulmonary disease: a nationwide study in Taiwan. Int J Chron Obstruct Pulmon Dis. 2019;14:1455–1464. https://doi.org/10.2147/COPD.S202029.

40.

Houben-Wilke S, Jorres RA, Bals R, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and systemic consequences-comorbidities network study. Am J Respir Crit Care Med. 2017;195:189–197. https://doi.org/10.1164/rccm.201602-0354OC.

41.

Tschopp J, Dumont P, Hayoz D. True prevalence of COPD and its association with peripheral arterial disease in the internal medicine ward of a tertiary care hospital. Swiss Med Wkly. 2017;147:w14460. https://doi.org/10.4414/smw.2017.14460.

42.

Terzikhan N, Lahousse L, Verhamme KMC, et al. COPD is associated with an increased risk of peripheral artery disease and mortality. ERJ Open Res. 2018;4. https://doi.org/10.1183/23120541.00086-2018.

43.

Willey J, Mentias A, Vaughan-Sarrazin M, et al. Epidemiology of lower extremity peripheral artery disease in veterans. J Vasc Surg. 2018;68:527–535 e525. https://doi.org/10.1016/j.jvs.2017.11.083.

44.

Yao CW, Shen TC, Lu CR, et al. Asthma is associated with a subsequent risk of peripheral artery disease: a longitudinal population-based study. Medicine (Baltimore). 2016;95:e2546. https://doi.org/10.1097/MD.0000000000002546.

45.

Tuleta I, Skowasch D, Aurich F, et al. Asthma is associated with atherosclerotic artery changes. PLoS One. 2017;12:e0186820. https://doi.org/10.1371/journal.pone.0186820.

46.

Portegies ML, Lahousse L, Joos GF, et al. Chronic obstructive pulmonary disease and the risk of stroke. The Rotterdam study. Am J Respir Crit Care Med. 2016;193:251–258. https://doi.org/10.1164/rccm.201505-0962OC.

47.

Truelsen T, Prescott E, Lange P, et al. Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study. Int J Epidemiol. 2001;30:145–151. https://doi.org/10.1093/ije/30.1.145.

48.

Gulsvik AK, Gulsvik A, Skovlund E, et al. The association between lung function and fatal stroke in a community followed for 4 decades. J Epidemiol Commun Health. 2012;66:1030–1036. https://doi.org/10.1136/jech-2011-200312.

49.

Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008. BMC Pulm Med. 2012;12:26. https://doi.org/10.1186/1471-2466-12-26.

50.

Silvestre OM, Nadruz W, Querejeta Roca G, et al. Declining lung function and cardiovascular risk: the ARIC study. J Am Coll Cardiol. 2018;72:1109–22. https://doi.org/10.1016/j.jacc.2018.06.049.CrossRefPubMedPubMedCentral

51.

Ching SM, Chia YC, Lentjes MAH, et al. FEV1 and total cardiovascular mortality and morbidity over an 18 years follow-up population-based prospective EPIC-NORFOLK study. BMC Public Health. 2019;19:1–10. https://doi.org/10.1186/s12889-019-6818-x.CrossRef

52.

Kim SY, Lim H, Lim JS, et al. Analysis of the relationship between adult asthma and stroke: a longitudinal follow-up study using the Korean national sample cohort. Biomed Res Int. 2019;2019:8919230. https://doi.org/10.1155/2019/8919230.

53.

Wen LY, Ni H, Li KS, et al. Asthma and risk of stroke: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2016;25:497–503. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.11.030.

54.

Strand LB, Tsai MK, Wen CP, et al. Is having asthma associated with an increased risk of dying from cardiovascular disease? A prospective cohort study of 446 346 Taiwanese adults. BMJ Open. 2018;8:e019992. https://doi.org/10.1136/bmjopen-2017-019992.

55.

Pollevick ME, Xu KY, Mhango G, et al. The relationship between asthma and cardiovascular disease: an examination of the Framingham offspring study. Chest. 2021;159:1338–1345. https://doi.org/10.1016/j.chest.2020.11.053.

56.

Kalhan R, Tran BT, Colangelo LA, et al. Systemic inflammation in young adults is associated with abnormal lung function in middle age. PLoS One. 2010;5:e11431. https://doi.org/10.1371/journal.pone.0011431.

57.

Kalhan R, Dransfield MT, Colangelo LA, et al. Respiratory symptoms in young adults and future lung disease. The CARDIA lung study. Am J Respir Crit Care Med. 2018;197:1616–1624. https://doi.org/10.1164/rccm.201710-2108OC.

58.

Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax. 2007;62:237–241. https://doi.org/10.1136/thx.2006.068379.

59.

King GG. Cutting edge technologies in respiratory research: lung function testing. Respirology. 2011;16:883–890. https://doi.org/10.1111/j.1440-1843.2011.02013.x.

60.

Silverman EK. Genetics of COPD. Annu Rev Physiol. 2020;82:413–431. https://doi.org/10.1146/annurev-physiol-021317-121224.

61.

Zhang L, Valizadeh H, Alipourfard I, et al. Epigenetic modifications and therapy in chronic obstructive pulmonary disease (COPD): An Update Review. COPD. 2020;17:333–342. https://doi.org/10.1080/15412555.2020.1780576.

62.

Sun P, Ye R, Wang C, et al. Identification of proteomic signatures associated with COPD frequent exacerbators. Life Sci. 2019;230:1–9. https://doi.org/10.1016/j.lfs.2019.05.047.

63.

Bowerman KL, Rehman SF, Vaughan A, et al. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat Commun. 2020;11:5886. https://doi.org/10.1038/s41467-020-19701-0.

Titel: Cardiovascular Morbidity in Individuals with Impaired FEV1
verfasst von: Joscilin Mathew
Nils Patrick Nickel
Publikationsdatum: 17.01.2022
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 3/2022
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-022-01636-1

Neu im Fachgebiet Kardiologie

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Associations of Glycemic Index and Glycemic Load with Cardiovascular Disease: Updated Evidence from Meta-analysis and Cohort Studies

SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes

Burden and Impact of Arrhythmias in Repaired Tetralogy of Fallot

Anesthetic Management in Adults with Congenital Heart Disease